Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) have earned an average rating of “Hold” from the six ratings firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.60.

DSGN has been the topic of several recent analyst reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday. Finally, Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Design Therapeutics in a report on Wednesday, March 20th.

Insider Transactions at Design Therapeutics

In other news, Director John P. Schmid bought 17,809 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were bought at an average cost of $3.74 per share, with a total value of $66,605.66. Following the acquisition, the director now owns 26,965 shares in the company, valued at $100,849.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Design Therapeutics news, Director John P. Schmid bought 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The stock was bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the transaction, the director now owns 26,965 shares in the company, valued at approximately $100,849.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John P. Schmid bought 9,156 shares of Design Therapeutics stock in a transaction dated Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, with a total value of $33,144.72. Following the transaction, the director now owns 9,156 shares of the company’s stock, valued at approximately $33,144.72. The disclosure for this purchase can be found here. 25.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BML Capital Management LLC acquired a new stake in Design Therapeutics during the 4th quarter valued at approximately $2,728,000. RTW Investments LP lifted its stake in Design Therapeutics by 60.8% during the 3rd quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock valued at $5,931,000 after acquiring an additional 949,955 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new position in Design Therapeutics during the 3rd quarter valued at $425,000. GSA Capital Partners LLP lifted its stake in Design Therapeutics by 199.3% during the 1st quarter. GSA Capital Partners LLP now owns 216,347 shares of the company’s stock valued at $872,000 after acquiring an additional 144,055 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Design Therapeutics by 41.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 347,794 shares of the company’s stock valued at $1,402,000 after purchasing an additional 102,567 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Stock Performance

Shares of DSGN stock opened at $4.69 on Thursday. The stock’s 50 day simple moving average is $3.44 and its 200 day simple moving average is $2.76. Design Therapeutics has a twelve month low of $1.94 and a twelve month high of $8.47. The company has a market capitalization of $264.94 million, a price-to-earnings ratio of -3.91 and a beta of 1.83.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings results on Tuesday, March 19th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.11. On average, analysts forecast that Design Therapeutics will post -1.26 EPS for the current fiscal year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.